Search Result

Results for "

Ubiquitination protein

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (2) ATGL (1) Autophagy (1) Bcl-2 Family (1) Bcr-Abl (1) Btk (1) CaMK (1) CDK (1) Deubiquitinase (4) DNA/RNA Synthesis (1) E1/E2/E3 Enzyme (5) E3 Ligase Ligand-Linker Conjugates (1) Endogenous Metabolite (1) Ferroptosis (1) Glutathione Peroxidase (1) HDAC (1) HIF/HIF Prolyl-Hydroxylase (1) Histone Methyltransferase (1) Ligands for E3 Ligase (8) MDM-2/p53 (1) Mitophagy (1) NF-κB (1) Phosphatase (1) PROTACs (10) Proteasome (1) Salt-inducible Kinase (SIK) (1) Tau Protein (1) TGF-beta/Smad (1)
By Research Areas:	Cancer (24) Inflammation/Immunology (1) Metabolic Disease (1) Neurological Disease (5)

By Targets:

Apoptosis (2)

ATGL (1)

Autophagy (1)

Bcl-2 Family (1)

Bcr-Abl (1)

Btk (1)

CaMK (1)

CDK (1)

Deubiquitinase (4)

DNA/RNA Synthesis (1)

E1/E2/E3 Enzyme (5)

E3 Ligase Ligand-Linker Conjugates (1)

Endogenous Metabolite (1)

Ferroptosis (1)

Glutathione Peroxidase (1)

HDAC (1)

HIF/HIF Prolyl-Hydroxylase (1)

Histone Methyltransferase (1)

Ligands for E3 Ligase (8)

MDM-2/p53 (1)

Mitophagy (1)

NF-κB (1)

Phosphatase (1)

PROTACs (10)

Proteasome (1)

Salt-inducible Kinase (SIK) (1)

Tau Protein (1)

TGF-beta/Smad (1)

By Research Areas:

Cancer (24)

Inflammation/Immunology (1)

Metabolic Disease (1)

Neurological Disease (5)

Inhibitors & Agonists

Screening Libraries

Natural
Products

Recombinant Proteins

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-124713

ML372	DNA/RNA Synthesis	Neurological Disease
ML372 inhibits survival motor neuron (SMN) protein ubiquitination, increases SMN protein stability without affecting mRNA expression. ML372 improves spinal muscular atrophy (SMA) in mice. ML372 is brain penetrant and has a reasonable exposure and half-life in vivo .

HY-164027

MyoMed 205	Proteasome	Others
MyoMed-205 is an inhibitor targeting the activity of MuRF1. MyoMed-205 prevents early diaphragmatic systolic dysfunction and atrophy due to unilateral diaphragmatic nerve denervation 12 hours later. MyoMed-205 reduces ubiquitination and subsequent proteasomal degradation of muscle proteins by inhibiting MuRF1 activity. MyoMed-205 increases levels of a protein that phosphorylates Akt (ser473), an important signaling molecule for muscle growth and maintenance. MyoMed-205 can be used to study and treat diaphragmatic dysfunction and atrophy (DIDD) caused by early apraxia, especially in clinical situations such as diaphragmatic paralysis or mechanical ventilation .

HY-135199

Ubiquitination-IN-1	E1/E2/E3 Enzyme	Cancer
Ubiquitination-IN-1 (compound 24) is a *ubiquitination* and Cksl-Skp2 protein-protein interaction (IC₅₀=0.17 μM) inhibitor. Ubiquitination-IN-1 increases levels of p27. Ubiquitination-IN-1 has the potential for treatment disease by blocking the degradation of tumor suppressors .

HY-112438

MF-094 4 Publications Verification	Deubiquitinase	Cancer
MF-094 is a potent and selective USP30 inhibitor with an IC₅₀ of 120 nM. MF-094 increases protein ubiquitination and accelerates mitophagy .

HY-141659

CMPD-39 1 Publications Verification	Deubiquitinase	Cancer
CMPD-39 is a selective USP30 inhibitor with an IC₅₀ of 0.02 μM. CMPD-39 increases protein ubiquitination and accelerates mitophagy .

HY-129653

E3 ligase Ligand 18	Ligands for E3 Ligase	Cancer
E3 ligase Ligand 18 is a ligand for E3 ubiquitin ligase. E3 ligase Ligand 18 can be connected to the ligand for protein by a linker to form PROTACs. PROTACs are inducers of ubiquitination-mediated degradation of cancer-promoting proteins .

HY-156959

Ovalicin	Others	Others
Ovalicin is a potent angiogenesis inhibitor. Ovalicin can be used for the preparation of targeting ubiquitination composition libraries which can be used to identify proteins involved in a predetermined function of cells .

HY-169133

GDCNF-11	PROTACs Glutathione Peroxidase Ferroptosis	Cancer
GDCNF-11 is a HIM-PROTAC GPX4 degrader based on the chaperone protein HSP90. GDCNF-11 promotes the ubiquitination and degradation of GPX4 through the HSP 90 chaperone complex, reduces endogenous GPX4 expression to induce ferroptosis in HT-1080 cells, and the DC₅₀ value is 0.08 μM (Pink: Target protein ligand (HY-153748); Blue: HSP90 ligand (HY-10212); Black: Linker (HY-W169526)) .

HY-128807

E3 ligase Ligand 10	Ligands for E3 Ligase	Cancer
E3 ligase Ligand 10 is a ligand for E3 ubiquitin ligase. E3 ligase Ligand 10 can be connected to the ligand for protein by a linker to form PROTACs. PROTACs are inducers of ubiquitination-mediated degradation of cancer-promoting proteins .

HY-128811

E3 ligase Ligand 14	Ligands for E3 Ligase	Cancer
E3 ligase Ligand 14 is a ligand for E3 ubiquitin ligase. E3 ligase Ligand 14 can be connected to the ligand for protein by a linker to form PROTACs. PROTACs are inducers of ubiquitination-mediated degradation of cancer-promoting proteins .

HY-43961

E3 ligase Ligand 8 3 Publications Verification	Ligands for E3 Ligase	Cancer
E3 ligase Ligand 8 is a ligand for E3 ubiquitin ligase. E3 ligase Ligand 8 can be connected to the ligand for protein by a linker to form PROTACs. PROTACs are inducers of ubiquitination-mediated degradation of cancer-promoting proteins .

HY-128810

E3 ligase Ligand 13	Ligands for E3 Ligase	Cancer
E3 ligase Ligand 13 is a ligand for E3 ubiquitin ligase. E3 ligase Ligand 13 can be connected to the ligand for protein by a linker to form PROTACs. PROTACs are inducers of ubiquitination-mediated degradation of cancer-promoting proteins .

HY-128806

E3 ligase Ligand 9	Ligands for E3 Ligase	Cancer
E3 ligase Ligand 9 is a ligand for E3 ubiquitin ligase. E3 ligase Ligand 9 can be connected to the ligand for protein by a linker to form PROTACs or SNIPERs. PROTACs are inducers of ubiquitination-mediated degradation of cancer-promoting proteins .

HY-131667

Hdm2 E3 ligase inhibitor 1	MDM-2/p53 E1/E2/E3 Enzyme	Cancer
Hdm2 E3 ligase inhibitor 1 (Compound 1) is a reversible inhibitor for Hdm2 (an E3 ubiquitin ligase)-mediated ubiquitination of the p53 protein with an IC₅₀ of 12.7 μM. Hdm2 E3 ligase inhibitor 1 binds Hdm2, blocks Hdm2-catalyzed ubiquitin transfer from preligated Ub-Ubc4 to p53, inhibits p53 ubiquitination, stabilizes p53 protein in tumor cell and exhibits antitumor efficacy .

HY-164539

TMU 35435	HDAC Autophagy	Cancer
TMU 35435 is a histone deacetylase (HDAC) inhibitor. TMU-35435 inhibits the NHEJ pathway through ubiquitination of DNA-dependent protein kinase catalytic subunit (DNA-PKcs). In addition, TMU 35435 enhances radiosensitivity by inducing misfolded protein aggregation and autophagy in TNBC .

HY-W020033

Lanosterol 3 Publications Verification	Endogenous Metabolite	Neurological Disease
Lanosterol is an intermediate of cholesterol synthesis and use of lanosterol induces ubiquitination and degradation of a rate-controlling enzyme of cholesterol synthesis, i.e., HMG CoA reductase. Lanosterol suppresses the aggregation and cytotoxicity of misfolded proteins linked with neurodegenerative diseases .

HY-112438A

rac-MF-094	Deubiquitinase	Cancer
rac-MF-094 is the racemic mixture of MF-094 (HY-112438). MF-094 is a potent and selective USP30 inhibitor with an IC₅₀ of 120 nM. MF-094 increases protein ubiquitination and accelerates mitophagy .

HY-138669

C004019	PROTACs Tau Protein	Neurological Disease
C004019 is a small-molecule PROTAC. C004019 simultaneously recruites tau and E3-ligase (Vhl) and thus selectively enhances ubiquitination and proteolysis of tau proteins. C004019 can be used for Alzheimer disease (AD) research .

HY-W1003189

E3 ligase Ligand 42	Ligands for E3 Ligase	Cancer
E3 ligase Ligand 42 is an E3 ubiquitin ligase ligand. E3 ligase Ligand 42 can be connected to the target protein ligand through a linker and can be used to synthesize PROTAC AR Degrader-6 (HY-156751). PROTAC can induce ubiquitination degradation of cancer-promoting proteins .

HY-147373

DA-PROTAC	PROTACs Ligands for E3 Ligase	Cancer
DA-PROTAC is a potent PROTAC degrader of copper ion-transport proteins Atox1 and CCS. DA-PROTAC can bind both Atox1 and CCS proteins, and the complex can be bound to E3 ligase, leading to increased levels of ubiquitination of Atox1 and CCS and degradation of Atox1 and CCS proteins via the proteasome pathway. DA-PROTAC can be used for triple negative breast cancer research .

HY-130297

PROTAC BCR-ABL1 ligand 1	Bcr-Abl	Cancer
PROTAC BCR-ABL1 ligand 1, compound GMB-475, is the ligand of PROTAC that allosterically targets BCR-ABL1 protein and recruits the E3 ligase Von Hippel-Lindau, resulting in ubiquitination and subsequent degradation of BCR-ABL1 .

HY-163743

SIC-19	Salt-inducible Kinase (SIK)	Cancer
SIC-19 is a SIK2 inhibitor and promotes SIK2 protein degradation via the ubiquitination pathway. SIC-19 inhibits cancer cell growth and sensitizes cells to PARP inhibitors (Such as Olaparib (HY-10162)), as well as in ovarian cancer organoids and xenograft models .

HY-157428

USP3 ZnF-UBD ligand-1	Others	Others
USP3 ZnF-UBD ligand-1 (compound 59) is a ligand that binds to the zinc finger ubiquitin-binding domain (ZnF-UBD) of USP3 with a K_D of 14 μM .

HY-157416

COP1-ATGL modulator 1	ATGL E1/E2/E3 Enzyme	Metabolic Disease
COP1-ATGL modulator 1 (86) is an orally active modulator for COP1-ATGL axis. COP1-ATGL modulator 1 (86) could increase ATGL protein expression, reduce ATGL ubiquitination and COP1 autoubiquitination, and diminish lipid accumulation in hepatocytes in the nanomolar range .

HY-160019

MTX115325	Deubiquitinase Mitophagy	Neurological Disease
MTX115325 (Example 1) is an orally active, brain-penetrating USP30 inhibitor (IC₅₀=12 nM) with neuroprotective activity. MTX115325 increases ubiquitination (EC₅₀=32 nM) of the mitochondrial outer membrane protein TOM20 (a USP30 substrate), increasing mitophagy. MTX115325 prevents dopaminergic neuron loss and preserves striatal dopamine .

HY-100487

TAK-243 Maximum Cited Publications 46 Publications Verification MLN7243	E1/E2/E3 Enzyme NF-κB Apoptosis	Cancer
TAK-243 (MLN7243) is a first-in-class, selective ubiquitin activating enzyme, UAE (UBA1) inhibitor (IC₅₀=1 nM), which blocks ubiquitin conjugation, disrupting monoubiquitin signaling as well as global protein ubiquitination. TAK-243 (MLN7243) induces endoplasmic reticulum (ER) stress, abrogates NF-κB pathway activation and promotes apoptosis .

HY-130269

β-Naphthoflavone-CH2-OH β-NF-CH2-OH	E3 Ligase Ligand-Linker Conjugates	Cancer
β-Naphthoflavone-CH2-OH (β-NF-CH2-OH) is a ligand for arylhydrocarbon receptor (AhR) E3 ligase. β-Naphthoflavone-CH2-OH can be connected to the ligand for protein by a linker to form PROTACs or SNIPERs (e.g., β-naphthoflavone-JQ1) that recruit the AhR E3 ligase complex by incorporating AhR ligands into chimeric molecules. PROTACs are inducers of ubiquitination-mediated degradation of cancer-promoting proteins .

HY-147025

(S,R,S)-AHPC-C2-amide-benzofuranylmethyl-pyridine 1 Publications Verification	PROTACs TGF-beta/Smad HIF/HIF Prolyl-Hydroxylase	Inflammation/Immunology
(S,R,S)-AHPC-C2-amide-benzofuranylmethyl-pyridine is a dual target PROTAC that can not only target to the ubiquitination and degradation of Smad3 but also improve the HIF-α protein level. (S,R,S)-AHPC-C2-amide-benzofuranylmethyl-pyridine has a multi-path anti-fibrosis function and a renal protection function for research of renal anemia .

HY-156104

CaMKIIα-PHOTAC	PROTACs CaMK	Neurological Disease
CaMKIIα-PHOTAC is a photochemically targeted chimera (PHOTAC) targeting Ca2+/calmodulin-dependent protein kinase II α (CaMKIIα). Molecules such as PHOTAC can catalyze the ubiquitination and degradation of target proteins through the endogenous proteasome under specific wavelengths of light. CaMKIIα-PHOTAC reduces synaptic function under light conditions, and it attenuates the intensity of evoked field excitatory postsynaptic potentials in the mouse hippocampus in response to physiological stimuli. CaMKIIα-PHOTAC plays a critical role in maintaining long-term potentiation and memory capacity in subcellular dendritic domains .

HY-163815

CDK2 degrader 2	PROTACs CDK	Others
CDK2 degrader 2 is a PROTAC class CDK2 degrader. The CDK2 binding moiety (CBM) binds to the CDK2 protein and subsequently undergoes ubiquitination, leading to the degradation of CDK2 through the ubiquitin proteasome pathway (UPP). CDK2 degrader 2 can cause degradation of CDK2 in MKN1 cells, with a DC₅₀ value less than 100 nM and an average D_max value greater than 75%. (Red: CBM; Blue: DIM; Black: linker)

HY-161410

WH244	PROTACs Apoptosis Bcl-2 Family	Cancer
WH244 is a second generation BCL-2 and BCL-xL dual depressant (PROTAC). The primary activity of WH244 is the specific degradation of BCL-2 and BCL-xL proteins (BCL-xL: DC₅₀=0.6 nM, BCL-2: DC₅₀=7.4 nM). WH244 promotes their ubiquitination and subsequent proteasome degradation by targeting these proteins, thereby restoring the cell's apoptosis pathway. WH244 has good antitumor activity. (Pink: BCL-2/BCL-xL ligand (HY-161415); Blue: E3 ligase ligand (HY-112078); Black: linker) .

HY-101508

GNA002	Histone Methyltransferase	Cancer
GNA002 is a highly potent, specific and covalent EZH2 (Enhancer of zeste homolog 2) inhibitor with an IC₅₀ of 1.1 μM. GNA002 can specifically and covalently bind to Cys668 within the EZH2-SET domain, triggering EZH2 degradation through COOH terminus of Hsp70-interacting protein (CHIP)-mediated ubiquitination. GNA002 efficiently reduces EZH2-mediated H3K27 trimethylation, reactivates polycomb repressor complex 2 (PRC2)-silenced tumor suppressor genes .

HY-153357

NRX-0492	PROTACs Btk	Cancer
NRX-0492 is an orally active PROTAC-class BTK degrader. NRX-0492 catalyzes BTK ubiquitination and proteasome degradation (DC₅₀ ≤ 0.2 nM, DC₉₀ ≤ 0.5 nM) . NRX-0492 inhibits B cell receptor (BCR) mediated signaling, transcription programs, and chemokine secretion. NRX-0492 can bind non-covalently to the BTK binding domain and cereblon, which is an adapter protein in the E3 ubiquitin ligase complex . NRX-0492 consists of a target protein ligand (red part) BTK-IN-40 (HY-170324), an E3 ligase ligand (blue part) Thalidomide 5-fluoride (HY-W087383), and a PROTAC linker (black part) (3R)-3-Pyrrolidinemethanol (HY-60263). E3 ubiquitin ligase and linker can form Thalidomide 5-pyrrolidine-CHO (HY-49372A); the active control for the target protein ligand is BTK ligand 12 (HY-49421).

HY-160924

MS147	PROTACs E1/E2/E3 Enzyme	Cancer
MS147 is a VHL-based PROTAC degrader of PRC1 (Polycomb Repressive Complex 1). The dissociation constants (Kd) of MS147 for EED (Embryonic Ectoderm Development) and VHL (Von Hippel-Lindau) are 3.0 μM and 450 nM, respectively. MS147 specifically binds to the EED protein through its EED-binding moiety; EED is a core component of PRC2 (Polycomb Repressive Complex 2) and interacts with the core components of PRC1, BMI1 (B-lymphoma Mo-MLV insertion region 1 homolog) and RING1B (Ring Finger Protein 1B). By this binding, MS147 is able to recruit BMI1 and RING1B near to VHL. Through the degradation of BMI1 and RING1B, MS147 reduces the level of H2AK119ub (histone H2A lysine 119 ubiquitination), affecting the proliferation of cancer cells. (Blue: VHL ligand (HY-125845), Black: linker ; Pink: PRC1 ligand (HY-158771)) .

HY-149760

PVD-06	PROTACs Phosphatase	Cancer
PVD-06 is a selective PROTAC-class PTPN2 degrader (PTPN2/PTP1B selectivity index >60-fold) with anticancer activity. PVD-06 induces PTPN2 degradation via ubiquitination and proteasome-dependent pathways. PVD-06 can promote T cell activation and amplify IFN-γ-mediated cytotoxicity . PVD-06 consists of a target protein ligand (red part) PTPN2 ligand 1 (HY-168691), a PROTAC linker (black part) 6-Aminocaproic acid (HY-B0236), and an E3 ubiquitin ligase ligand (blue part) (S,R,S)-AHPC-Me (HY-112078). E3 ubiquitin ligase+linker can form 6-Aminocaproic acid-(S,R,S)-AHPC-Me (HY-168690).

Cat. No.	Product Name

HY-L050

Ubiquitination Compound Library	301 compounds
Protein ubiquitination is an enzymatic post-translational modification in which an ubiquitin protein is attached to a substrate protein. Ubiquitination involves three main steps: activation, conjugation, and ligation, performed by ubiquitin-activating enzymes (E1s), ubiquitin-conjugating enzymes (E2s), and ubiquitin ligases (E3s), respectively. Ubiquitination affects cellular processes such as apoptosis, cell cycle, DNA damage repair, and membrane transportation, etc. by regulating the degradation of proteins (via the proteasome and lysosome), altering the cellular localization of proteins, affecting proteins activity, and promoting or preventing protein-protein interactions. Deregulation of ubiquitin pathway leads to many diseases such as neurodegeneration, cancer, infection and immunity, etc. MCE offers a unique collection of 301 small molecule modulators with biological activity used for ubiquitination research. Compounds in this library target the key enzymes in ubiquitin pathway. MCE Ubiquitination Compound Library is a useful tool for the research of ubiquitination regulation and the corresponding diseases.

Ubiquitination Compound Library

301 compounds

Protein ubiquitination is an enzymatic post-translational modification in which an ubiquitin protein is attached to a substrate protein. Ubiquitination involves three main steps: activation, conjugation, and ligation, performed by ubiquitin-activating enzymes (E1s), ubiquitin-conjugating enzymes (E2s), and ubiquitin ligases (E3s), respectively. Ubiquitination affects cellular processes such as apoptosis, cell cycle, DNA damage repair, and membrane transportation, etc. by regulating the degradation of proteins (via the proteasome and lysosome), altering the cellular localization of proteins, affecting proteins activity, and promoting or preventing protein-protein interactions. Deregulation of ubiquitin pathway leads to many diseases such as neurodegeneration, cancer, infection and immunity, etc.

MCE offers a unique collection of 301 small molecule modulators with biological activity used for ubiquitination research. Compounds in this library target the key enzymes in ubiquitin pathway. MCE Ubiquitination Compound Library is a useful tool for the research of ubiquitination regulation and the corresponding diseases.

HY-L137

Molecular Glue Compound Library	54 compounds
Targeted protein degradation(TPD) is a novel and promising approach to new drug discovery and development. It shows great potential for treating diseases with “undruggable” pathogenic protein targets and for overcoming drug resistance. Molecular glues and PROTACs are both targeted protein degraders that have attracted the most attention. Molecular glues are small molecular degraders that mainly induce novel interaction between an E3 ligase and a target protein to form a ternary complex, leading to protein ubiquitination and subsequent proteasome degradation. Compared with PROTACs, molecular glues generally possess more favorable drug-like properties, such as lower MW, higher cell permeability, and better oral absorption. Molecular glues are emerging as a promising new therapeutic strategy. MCE supplies a unique collection of 54 molecular glues which target various proteins. MCE Molecular Glue Compound Library is a useful tool to conduct scientific research and disease mechanism study.

Molecular Glue Compound Library

54 compounds

Targeted protein degradation(TPD) is a novel and promising approach to new drug discovery and development. It shows great potential for treating diseases with “undruggable” pathogenic protein targets and for overcoming drug resistance. Molecular glues and PROTACs are both targeted protein degraders that have attracted the most attention.

Molecular glues are small molecular degraders that mainly induce novel interaction between an E3 ligase and a target protein to form a ternary complex, leading to protein ubiquitination and subsequent proteasome degradation. Compared with PROTACs, molecular glues generally possess more favorable drug-like properties, such as lower MW, higher cell permeability, and better oral absorption. Molecular glues are emerging as a promising new therapeutic strategy.

MCE supplies a unique collection of 54 molecular glues which target various proteins. MCE Molecular Glue Compound Library is a useful tool to conduct scientific research and disease mechanism study.

HY-L129

Target Protein Ligand Library	53 compounds
Proteolysis-targeting chimera (PROTAC) has been developed to be a useful technology for targeted protein degradation. PROTACs consist of a ligand for E3 ligase (E3 ligase binder), a linker and a ligand (mostly small-molecule inhibitor) for protein of interest（target binder）. Upon binding to the target protein, the PROTACs can recruit E3 for target protein ubiquitination, which is subjected to proteasome-mediated degradation. Therefore, PROTACs execute their functions by degrading the target proteins rather than inhibiting them, which has a great superiority in overcoming resistance caused by target mutation or overexpression. To date, PROTAC technology has been applied to a variety of targets, including AR, ER, BTK, BET, and BCR-ABL to overcome resistance. MCE carefully prepared a unique collection of 53 ligands for target proteins, which have been reported to be used in PROTAC design. MCE Target Protein Ligand Library is a useful tool for PROTAC development.

Target Protein Ligand Library

53 compounds

Proteolysis-targeting chimera (PROTAC) has been developed to be a useful technology for targeted protein degradation. PROTACs consist of a ligand for E3 ligase (E3 ligase binder), a linker and a ligand (mostly small-molecule inhibitor) for protein of interest（target binder）. Upon binding to the target protein, the PROTACs can recruit E3 for target protein ubiquitination, which is subjected to proteasome-mediated degradation. Therefore, PROTACs execute their functions by degrading the target proteins rather than inhibiting them, which has a great superiority in overcoming resistance caused by target mutation or overexpression. To date, PROTAC technology has been applied to a variety of targets, including AR, ER, BTK, BET, and BCR-ABL to overcome resistance.

MCE carefully prepared a unique collection of 53 ligands for target proteins, which have been reported to be used in PROTAC design. MCE Target Protein Ligand Library is a useful tool for PROTAC development.

HY-L128

E3 Ligase Ligand Library	60 compounds
Proteolysis-targeting chimera (PROTAC) has been developed to be a useful technology for targeted protein degradation. PROTACs consist of a ligand for E3 ligase (E3 ligase binder), a linker and a ligand (mostly small-molecule inhibitor) for protein of interest（target binder）. Upon binding to the target protein, the PROTACs can recruit E3 for target protein ubiquitination, which is subjected to proteasome-mediated degradation. Although there are more than 600 E3 ubiquitin ligases, only several with small molecule ligands have been used for designing PROTACs, including Skp1-Cullin-F box complex containing Hrt1 (SCF), Von Hippel-Lindau tumor suppressor (VHL), Cereblon (CRBN), inhibitor of apoptosis proteins (IAPs), and mouse double minute 2 homolog (MDM2). MCE carefully prepared a unique collection of 60 ligands for E3 ligase, which have been reported to be used in PROTAC design. MCE E3 ligase ligand library is a useful tool for PROTAC development.

E3 Ligase Ligand Library

60 compounds

Although there are more than 600 E3 ubiquitin ligases, only several with small molecule ligands have been used for designing PROTACs, including Skp1-Cullin-F box complex containing Hrt1 (SCF), Von Hippel-Lindau tumor suppressor (VHL), Cereblon (CRBN), inhibitor of apoptosis proteins (IAPs), and mouse double minute 2 homolog (MDM2).

MCE carefully prepared a unique collection of 60 ligands for E3 ligase, which have been reported to be used in PROTAC design. MCE E3 ligase ligand library is a useful tool for PROTAC development.

Lanosterol 3 Publications Verification	Triterpenes Structural Classification Human Gut Microbiota Metabolites Microorganisms Terpenoids Source classification Endogenous metabolite	Endogenous Metabolite
Lanosterol is an intermediate of cholesterol synthesis and use of lanosterol induces ubiquitination and degradation of a rate-controlling enzyme of cholesterol synthesis, i.e., HMG CoA reductase. Lanosterol suppresses the aggregation and cytotoxicity of misfolded proteins linked with neurodegenerative diseases .

Species:	Human (3)
Tag:	His (1) Tag Free (1) GST (1)
Source:	E. coli (3)

Cat. No.	Compare	Product Name	Species	Source

HY-P701512

	SMURF2 Protein, Human (His) SMURF2; E3 ubiquitin-protein ligase SMURF2; hSMURF2; HECT-type E3 ubiquitin transferase SMURF2; SMAD Ubiquitination regulatory factor 2; SMAD-specific E3 ubiquitin-protein ligase 2	Human	E. coli
	SMURF2 protein is an E3 ubiquitin protein ligase that interacts with SMAD7 to induce ubiquitin-dependent degradation of TGF-β receptors and downregulate TGF-β signaling. This interaction triggers autocatalytic degradation of SMURF2 and is antagonized by AIMP1. SMURF2 Protein, Human (His) is the recombinant human-derived SMURF2 protein, expressed by E. coli , with N-6*His labeled tag. The total length of SMURF2 Protein, Human (His) is 747 a.a., .

HY-P701513

	SMURF2 Protein, Human SMURF2; E3 ubiquitin-protein ligase SMURF2; hSMURF2; HECT-type E3 ubiquitin transferase SMURF2; SMAD Ubiquitination regulatory factor 2; SMAD-specific E3 ubiquitin-protein ligase 2	Human	E. coli
	SMURF2 protein is an E3 ubiquitin protein ligase that interacts with SMAD7 to induce ubiquitin-dependent degradation of TGF-β receptors and downregulate TGF-β signaling. This interaction triggers autocatalytic degradation of SMURF2 and is antagonized by AIMP1. SMURF2 Protein, Human is the recombinant human-derived SMURF2 protein, expressed by E. coli , with tag free. The total length of SMURF2 Protein, Human is 747 a.a., .

HY-P700392

	UBAC1 Protein, Human (GST) UBAC1; UBA domain containing 1; UBADC1, ubiquitin associated domain containing 1; ubiquitin-associated domain-containing protein 1; GBDR1; UBA domain-containing protein 1; E3 ubiquitin-protein ligase subunit KPC2; ubiquitin associated domain containing 1; kip1 Ubiquitination-promoting complex protein 2; glialblastoma cell differentiation-related protein 1; putative glialblastoma cell differentiation-related protein; UBADC1; RP11-432J22.3	Human	E. coli
	The UBAC1 protein is a non-catalytic component of the KPC complex and contributes to polyubiquitination, targeting proteins such as CDKN1B and NFKB1. The KPC complex regulates the cell cycle by ubiquitinating and degrading CDKN1B during G1 phase. UBAC1 Protein, Human (GST) is the recombinant human-derived UBAC1 protein, expressed by E. coli , with N-GST labeled tag. The total length of UBAC1 Protein, Human (GST) is 405 a.a., with molecular weight of 72.3 kDa.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks